🟢 BioXcel Therapeutics is trading 8.4% up today after Teva proposed asset acquisition

BioXcel Therapeutics is trading at $0.12 (+8.41%) after Teva proposed acquiring substantially all assets in its Chapter 11 asset-sale process.

• The proposal includes IGALMI, $57.5 million upfront, and up to $67.5 million in contingent payments.
• The transaction remains subject to a court-supervised auction and approval.
• Broader biotechnology strength provides additional support amid continued volatility.